MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-28-2026
Galapagos NV Cash and Cash Equivalents 2011-2026 | GLPG
Annual Cash and Cash Equivalents Galapagos NV
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64.2 M | 167 M | 508 M | 2.23 B | 2.14 B | 1.86 B | 1.29 B | 1.15 B | 973 M | 340 M | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.23 B | 64.2 M | 1.07 B |
Quarterly Cash and Cash Equivalents Galapagos NV
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 2.23 B | - | 2.64 B | - | 2.14 B | - | 2.38 B | - | 1.86 B | - | 1.15 B | - | 1.29 B | - | 1.07 B | - | 1.15 B | - | 1.26 B | - | 973 M | - | - | - | 340 M | - | - | - | 188 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.64 B | 188 M | 1.44 B |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
129 M | $ 3.44 | -4.32 % | $ 1.03 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K |  USA |
 |
Aptorum Group Limited
APM
|
3.5 M | $ 0.79 | -1.15 % | $ 4.31 M |  China |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | China |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
ADMA Biologics
ADMA
|
87.6 M | $ 15.36 | -2.17 % | $ 3.66 B | USA |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Apellis Pharmaceuticals
APLS
|
466 M | $ 20.28 | 0.65 % | $ 2.56 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.51 | 1.35 % | $ 385 M | Britain |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Anika Therapeutics
ANIK
|
72.9 M | $ 14.05 | -1.44 % | $ 206 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
145 M | $ 74.36 | -1.64 % | $ 1.44 B | USA |
 |
Applied Therapeutics
APLT
|
49.9 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Athersys
ATHX
|
37.4 M | - | 3.77 % | $ 22.4 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
70.5 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
323 M | $ 162.43 | 0.6 % | $ 8.08 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
105 M | $ 8.49 | -0.18 % | $ 1.75 B | USA |
 |
BridgeBio Pharma
BBIO
|
570 M | $ 65.66 | -0.78 % | $ 12.6 B | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
187 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
6.92 M | - | -74.18 % | $ 955 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
21.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | Canada |
 |
BioLineRx Ltd.
BLRX
|
10.4 M | $ 2.69 | -0.74 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
1.31 B | $ 61.3 | 1.21 % | $ 11.8 B | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 7.79 | -5.75 % | $ 1.28 B | Britain |
 |
CymaBay Therapeutics
CBAY
|
207 M | - | - | $ 3.45 B | USA |
 |
Codexis
CDXS
|
19.3 M | $ 1.23 | -2.38 % | $ 90.3 M | USA |
 |
Cabaletta Bio
CABA
|
193 M | $ 3.18 | -0.16 % | $ 3.71 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
6.6 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
143 M | - | -7.23 % | $ 13 M | USA |